Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0005 Transporter Info
Gene Name SLC22A7
Transporter Name Organic anion transporter 2
Gene ID
10864
UniProt ID
Q9Y694
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Probenecid

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Probenecid inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (Ki = 766 microM) [1]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  DT Modulation 2

 Probenecid inhibits the activity of SLC22A7 [1]

  Ketoprofen

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ketoprofen inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 400 microM) [2]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  DT Modulation 2

 Ketoprofen inhibits the transportation of Salicylate by SLC22A7 (IC50 = 400 microM) [3]

Affected Drug/Substrate

 Salicylate Modulation Type Inhibition

  Theophylline

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Theophylline inhibits the transportation of Erythromycin by SLC22A7 [4]

Affected Drug/Substrate

 Erythromycin Modulation Type Inhibition

Cell System

 Oocytes-OAT2

  DT Modulation 2

 Theophylline inhibits the activity of SLC22A7 [4]

  Bumetanide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bumetanide inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 77.5 microM) [6]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Chlorothiazide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chlorothiazide inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 2205 microM) [6]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Cyclothiazide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyclothiazide inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 39.2 microM) [6]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Ethacrynic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ethacrynic acid inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 121 microM) [6]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Furosemide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Furosemide inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 603 microM) [6]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Hydrochlorothiazide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Hydrochlorothiazide inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 1023 microM) [6]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Trichlormethiazide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Trichloromethiazide inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 1120 microM) [6]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Diclofenac

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Diclofenac inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 14.3 microM) [2]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Ibuprofen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ibuprofen inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 692 microM) [2]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Indomethacin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Indomethacin inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 64.1 microM) [2]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Mefenamic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mefenamic acid inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 21.7 microM) [2]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Naproxen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Naproxen inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 486 microM) [2]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Piroxicam

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Piroxicam inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 70.3 microM) [2]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Sulindac

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sulindac inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 440 microM) [2]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Cefamandole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefamandole inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 1570 microM) [7]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Cefoperazone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefoperazone inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 1330 microM) [7]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Cefotaxime

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefotaxime inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 4680 microM) [7]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Cephalothin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cephalothin inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 1410 microM) [7]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Vorinostat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vorinostat inhibits histone deacetylases, which then enhances the expression of SLC22A7, and enhances zidovudine's transportation [8]

Affected Drug/Substrate

 zidovudine Modulation Type Inducer

Cell System

 Hepatocellular carcinoma cell lines (BEL-7402 and SMMC-7721)

  Minocycline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Minocycline inhibits the transportation of Prostaglandin F2alpha by SLC22A7 [10]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Oxytetracycline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Oxytetracycline inhibits the transportation of Prostaglandin F2alpha by SLC22A7 [10]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Zidovudine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zidovudine inhibits the transportation of Prostaglandin F2alpha by SLC22A7 [11]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Phenobarbital

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phenobarbital inhibits the expression of SLC22A7 [12]

Regulation Mechanism

 via modulation of Nuclear receptor subfamily 1 group I member 3 (NR1I3) Transcription Factor Info

Cell System

 Human primary human hepatocytes

  Rifampin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rifampin inhibits the expression of SLC22A7 [12]

Regulation Mechanism

 via modulation of Nuclear receptor subfamily 1 group I member 2 (NR1I2) Transcription Factor Info

Cell System

 Human primary human hepatocytes

  Chenodeoxycholic acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chenodeoxycholic acid inhibits the expression of SLC22A7 [13]

Regulation Mechanism

 via the inhibition of Hepatocyte nuclear factor 4-alpha (HNF4A) Transcription Factor Info

Cell System

 Human adult hepatocellular carcinoma cells (Huh7)

  Aspirin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Aspirin inhibits the activity of SLC22A7 [2]

  Methotrexate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methotrexate increases the expression of SLC22A7 [14]

  Rosiglitazone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rosiglitazone inhibits the expression of SLC22A7 [15]

  Urethane

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Urethane inhibits the expression of SLC22A7 [16]

  Valproic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valproic Acid inhibits the expression of SLC22A7 [17]

  Tamoxifen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tamoxifen increases the expression of SLC22A7 [18]

  Bosentan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bosentan affects the expression of SLC22A7 [19]

  Cyclosporine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyclosporine inhibits the expression of SLC22A7 [20]

  Acetaminophen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Acetaminophen inhibits the expression of SLC22A7 [21]

  Erythromycin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Erythromycin inhibits the activity of SLC22A7 [4]

  Salicylic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Salicylic acid inhibits the activity of SLC22A7 [22]

  Estradiol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Estradiol induces the activity of SLC22A7 [23]

Drug in Phase 3 Trial

  Oltipraz

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Oltipraz inhibits the expression of SLC22A7 [12]

Drug in Phase 2 Trial

  Bisphenol A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bisphenol A affects the expression of SLC22A7 [31]

Drug in Phase 1 Trial

  Sodium arsenite

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sodium arsenite inhibits the expression of SLC22A7 [29]

Drug Withdrawn

  Phenacetin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phenacetin inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 1878 microM) [2]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Cephaloridine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cephaloridine inhibits the transportation of Prostaglandin F2alpha by SLC22A7 (IC50 = 4480 microM) [7]

Affected Drug/Substrate

 Prostaglandin F2alpha Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

Natural Product

  Cigarette smoke condensate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cigarette smoke condensate inhibits the activity of SLC22A7 (IC50 = 16.9 microM) [9]

Cell System

 Human hepatoma HepaRG cells-OAT2

  Coal Ash

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Coal Ash increases the expression of SLC22A7 [24]

  Particulate Matter

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Particulate Matter inhibits the expression of SLC22A7 [25]

  Heliotrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Heliotrine inhibits the expression of SLC22A7 [26]

  Senecionine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Senecionine inhibits the expression of SLC22A7 [26]

  Tobacco Smoke Pollution

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tobacco Smoke Pollution inhibits the expression of SLC22A7 [9]

  Methyleugenol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methyleugenol inhibits the expression of SLC22A7 [32]

Environmental toxicant

  Polychlorinated dibenzodioxin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Polychlorinated dibenzodioxin inhibits the expression of SLC22A7 [9]

Mycotoxins

  Aflatoxin B1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Aflatoxin B1 inhibits the transportation of Organic anion by SLC22A7 (IC50 = 1502 microM) [5]

Affected Drug/Substrate

 Organic anion Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Alpha-zearalenol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Alpha-zearalenol inhibits the transportation of Organic anion by SLC22A7 (IC50 = 180 microM) [5]

Affected Drug/Substrate

 Organic anion Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Citrioveridine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Citrioveridine inhibits the transportation of Organic anion by SLC22A7 (IC50 > 1000 microM) [5]

Affected Drug/Substrate

 Organic anion Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Cyclopiazonic acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyclopiazonic acid inhibits the transportation of Organic anion by SLC22A7 (IC50 = 126 microM) [5]

Affected Drug/Substrate

 Organic anion Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Fumonisin B1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fumonisin B1 inhibits the transportation of Organic anion by SLC22A7 [5]

Affected Drug/Substrate

 Organic anion Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Patulin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Patulin inhibits the transportation of Organic anion by SLC22A7 [5]

Affected Drug/Substrate

 Organic anion Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Gliotoxin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Gliotoxin inhibits the transportation of Organic anion by SLC22A7 [5]

Affected Drug/Substrate

 Organic anion Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

  Zearalenone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zearalenone inhibits the transportation of Organic anion by SLC22A7 (IC50 = 149 microM) [5]

Affected Drug/Substrate

 Organic anion Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OAT2

Carcinogen

  Benzo(a)pyrene

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzo(a)pyrene inhibits the expression of SLC22A7 [32]

Fungicide

  Tebuconazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tebuconazole inhibits the expression of SLC22A7 [30]

Pesticide/Insecticide

  Endosulfan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Endosulfan inhibits the expression of SLC22A7 [27]

Health and Environmental Toxicant

  tris(1,3-dichloro-2-propyl)phosphate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC22A7 [28]
References
1 Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther. 2002 Jun;301(3):797-802.
2 Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
3 Characterization of Organic Anion Transporter 2 (SLC22A7): A Highly Efficient Transporter for Creatinine and Species-Dependent Renal Tubular Expression. Drug Metab Dispos. 2015 Jul;43(7):984-93.
4 Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
5 Interactions of organic anion transporters and organic cation transporters with mycotoxins. J Pharmacol Sci. 2008 Mar;106(3):435-43.
6 Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.
7 Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics. Eur J Pharmacol. 2003 Mar 28;465(1-2):1-7.
8 Proteomic and Biochemical Studies of Lysine Malonylation Suggest Its Malonic Aciduria-associated Regulatory Role in Mitochondrial Function and Fatty Acid Oxidation. Mol Cell Proteomics. 2015 Nov;14(11):3056-71.
9 Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate. Toxicology. 2016 Jul 1;363-364:58-71.
10 Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
11 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
12 Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos. 2006 Oct;34(10):1756-63.
13 The human organic anion transporter 2 gene is transactivated by hepatocyte nuclear factor-4 alpha and suppressed by bile acids. Mol Pharmacol. 2005 May;67(5):1629-38.
14 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
15 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
16 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
17 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
18 The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes. Arch Toxicol. 2018 Mar;92(3):1099-1112.
19 Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
20 Integrative "-Omics" Analysis in Primary Human Hepatocytes Unravels Persistent Mechanisms of Cyclosporine A-Induced Cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
21 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
22 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG02883)
23 Sex hormone-regulated renal transport of perfluorooctanoic acid. Chem Biol Interact. 2002 Mar 20;139(3):301-16.
24 Endothelial effects of emission source particles: acute toxic response gene expression profiles. Toxicol In Vitro. 2009 Feb;23(1):67-77.
25 Regulation of human hepatic drug transporter activity and expression by diesel exhaust particle extract. PLoS One. 2015 Mar 24;10(3):e0121232.
26 Disturbance of gene expression in primary human hepatocytes by hepatotoxic pyrrolizidine alkaloids: A whole genome transcriptome analysis. Toxicol In Vitro. 2015 Oct;29(7):1669-82.
27 Two persistent organic pollutants which act through different xenosensors (alpha-endosulfan and 2,3,7,8 tetrachlorodibenzo-p-dioxin) interact in a mixture and downregulate multiple genes involved in human hepatocyte lipid and glucose metabolism. Biochimie. 2015 Sep;116:79-91.
28 Defensive and adverse energy-related molecular responses precede tris (1, 3-dichloro-2-propyl) phosphate cytotoxicity. J Appl Toxicol. 2016 May;36(5):649-58.
29 Cellular and Molecular Effects of Prolonged Low-Level Sodium Arsenite Exposure on Human Hepatic HepaRG Cells. Toxicol Sci. 2018 Apr 1;162(2):676-687.
30 The azole fungicide tebuconazole affects human CYP1A1 and CYP1A2 expression by an aryl hydrocarbon receptor-dependent pathway. Food Chem Toxicol. 2019 Jan;123:481-491.
31 Comprehensive analysis of transcriptomic changes induced by low and high doses of bisphenol A in HepG2 spheroids in vitro and rat liver in vivo. Environ Res. 2019 Jun;173:124-134.
32 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.